Patents by Inventor Robert G. Korneluk

Robert G. Korneluk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mammalian IAP gene family, primers, probes and detection methods
    Patent number: 6689562
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: February 10, 2004
    Assignee: AEGERA Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • Antisense IAP nucleic acids and uses thereof
    Patent number: 6673917
    Abstract: The present invention feature antisense IAP nucleic acids and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 6, 2004
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Holcik, Sean Young
  • Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
    Patent number: 6656704
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: December 2, 2003
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • XAF genes and polypeptides: methods and reagents for modulating apoptosis
    Publication number: 20030215824
    Abstract: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Application
    Filed: November 5, 2002
    Publication date: November 20, 2003
    Applicant: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Katsuyuki Tamai, Peter Liston, Alexander E. MacKenzie
  • Methods and reagents for peptide-BIR interaction screens
    Publication number: 20030157522
    Abstract: The invention features a substantially pure polypeptide having a length of less than 100 amino acids and capable of forming a complex with a polypeptide that includes a BIR domain. The invention also features displacement assays in which the ability of a candidate compound to disrupt the interaction between a BIR domain-containing polypeptide and a polypeptide of the invention is indicative of the ability of the candidate compound to modulate IAP biological activity.
    Type: Application
    Filed: November 12, 2002
    Publication date: August 21, 2003
    Inventors: Alain Boudreault, Robert G. Korneluk, Eric LaCasse, Peter Liston
  • Mammalian IAP gene family, primers, probes and detection methods
    Patent number: 6541457
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP-family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: April 1, 2003
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • Method of identifying a compound that modulates XAF-mediated apoptosis
    Patent number: 6495339
    Abstract: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: December 17, 2002
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Katsuyuki Tamai, Peter Liston, Alexander E. MacKenzie
  • MAMMALIAN IAP GENE FAMILY, PRIMERS, PROBES AND DETECTION METHODS
    Publication number: 20020187946
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Application
    Filed: December 1, 1998
    Publication date: December 12, 2002
    Inventors: ROBERT G. KORNELUK, ALEXANDER E. MACKENZIE, STEPHEN BAIRD, PETER LISTON
  • USE OF NEURONAL APOPTOSIS INHIBITOR PROTEIN (NAIP)
    Publication number: 20020137028
    Abstract: The invention provides NAIP nucleic acid and sequences. Also provided are antiNAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Application
    Filed: September 12, 1997
    Publication date: September 26, 2002
    Inventors: ROBERT G KORNELUK, ALEXANDER E. MACKENZIE, NATALIE ROY, GEORGE ROBERTSON, KATSU TAMAI
  • Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease
    Publication number: 20020120121
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Application
    Filed: October 9, 2001
    Publication date: August 29, 2002
    Inventors: Robert G. Korneluk, Alexander E. Mackenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Neuronal apoptosis inhibitor protein gene sequence and mutations causative of spinal muscular atrophy
    Patent number: 6429011
    Abstract: The gene for autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: August 6, 2002
    Assignees: University of Ottawa, Research Development Corporation of Japan
    Inventors: Alex E. MacKenzie, Robert G. Korneluk, Natalie Roy, Mani S. Mahadevan, Michael McLean, Joh-E Ikeda
  • Methods and compounds for modulating male fertility
    Publication number: 20020086409
    Abstract: The invention features methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
    Type: Application
    Filed: December 18, 2001
    Publication date: July 4, 2002
    Inventors: Robert G. Korneluk, Mark Lagace
  • Methods and compounds for modulating male fertility
    Patent number: 6331412
    Abstract: The invention features novel methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: December 18, 2001
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Mark Lagacé
  • Modulation of IAPs for the diagnosis and antisense treatment of proliferative disease
    Patent number: 6300492
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: October 9, 2001
    Assignee: Aegera Therapeutics Inc.
    Inventors: Robert G. Korneluk, Alexander E. Mackenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
    Publication number: 20010021699
    Abstract: NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.
    Type: Application
    Filed: February 20, 2001
    Publication date: September 13, 2001
    Applicant: University of Ottawa
    Inventors: George S. Robertson, Robert G. Korneluk, Alexander E. MacKenzie, Daigen Xu, Stephen J. Crocker
  • XIAP IRES and uses thereof
    Patent number: 6171821
    Abstract: The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: January 9, 2001
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Martin Holcik, Peter Liston
  • Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
    Patent number: 6159948
    Abstract: NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: December 12, 2000
    Assignee: University of Ottawa
    Inventors: George S. Robertson, Robert G. Korneluk, Alexander E. MacKenzie, Daigen Xu, Stephen J. Crocker
  • XIAP IRES and uses thereof
    Patent number: 6159709
    Abstract: The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: December 12, 2000
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Martin Holcik, Peter Liston
  • Mammalian IAP gene family, primers, probes, and detection methods
    Patent number: 6156535
    Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: December 5, 2000
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
  • Modulation of IAPs for the treatment of proliferative diseases
    Patent number: 6133437
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: October 17, 2000
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt